John McLean

Medicine & Life Sciences

1. PAR-2 Receptor 100%
2. 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide 78%
3. Indomethacin 71%
4. Joints 70%
5. Cyclooxygenase 1 67%
6. Prostaglandins 62%
7. Knee 55%
8. Prostaglandin-Endoperoxide Synthases 55%
9. Hyperemia 45%
10. 3T3 Cells 45%
11. Arthritis 43%
12. Viral Tumor Antigens 42%
13. Primary Cell Culture 42%
14. Inflammation 41%
15. Serum-Free Culture Media 39%
16. NG-Nitroarginine Methyl Ester 39%
17. Umbilical Cord 39%
18. Carrageenan 34%
19. Endothelial Cells 30%
20. Knee Joint 29%
21. Intercellular Signaling Peptides and Proteins 28%
22. Perfusion 26%
23. Dinoprostone 25%
24. Macrophages 24%
25. Insulin 23%
26. Plasminogen Inactivators 23%
27. Analysis of Variance 22%
28. Cyclooxygenase 2 21%
29. Nitric Oxide 21%
30. Protein Isoforms 21%
31. Intra-Articular Injections 19%
32. Vascular Resistance 19%
33. Lasers 18%
34. Tissue Plasminogen Activator 18%
35. Nitric Oxide Synthase Type II 18%
36. Messenger RNA 18%
37. Rheumatoid Arthritis 17%
38. Cyclooxygenase Inhibitors 17%
39. Cyclooxygenase 2 Inhibitors 17%
40. 2-furoyl-leucyl-isoleucyl-glycyl-lysyl-valine 16%
41. Kaolin 16%
42. Serum 15%
43. mouse F2rl1 protein 13%
44. 1-3-methylbutyryl-N4-6-aminohexanoyl-piperazine 12%
45. Reverse Transcriptase Polymerase Chain Reaction 11%
46. Therapeutics 11%
47. Cell Line 10%
48. Anti-Inflammatory Agents 10%
49. Growth 10%
50. Maintenance 10%